Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 4/2013

01-10-2013 | Short Communication

Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio

Authors: Jun Chen, Rong-Rong Hu, Xi-Xiong Yang, Wei Gu, Rong Tian, Fang Gong, Lei Luo, Fang Fang, Zhi-Peng Chen, Bao-Chang Cai

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2013

Login to get access

Abstract

Purpose

Since the carboxylate form could be regarded as a possible “source” of lactone form, the optimum ratio of lactone should be determined for the administration of camptothecin (CPT) analogues such as 9-nitrocamptothecin (9-NC).

Methods

9-NC solutions with different lactone ratios (100, 75, 50, 25 and 0 %) were obtained by the change of pH. The resultant 9-NC solution and corresponding blank solvent were intravenously injected to mice to evaluate toxicity. The S180 tumor-bearing mice were intravenously administered 9-NC solutions with different lactone ratios, and the antitumor efficacy and toxicity were compared. The tissue distribution of lactone and total (the total of lactone and carboxylate forms) 9-NC was also investigated as a function of lactone ratio.

Results

Toxicity of 9-NC was found to be increased with the increase in lactone ratio. The tumor inhibitory rates of 9-NC solution were determined to be 64.17, 60.43, 42.78, 41.71 and 8.60 % for 100, 75, 50, 25 and 0 % lactone ratio, respectively. The lactone stability of 9-NC in most tissues was found to be higher than in plasma. In tumor and plasma, whether for lactone or total 9-NC AUC values, there was no difference between 100 and 75 % groups.

Conclusions

Although carboxylate form of CPTs is inactive, the administration of carboxylate form in an appropriate ratio is active as a result of its conversion to lactone form in vivo.
Literature
1.
go back to reference Venditto VJ, Simanek EE (2010) Cancer therapy utilizing the camptothecins: a review of the in vivo literature. Mole Pharmaceut 7:307–349CrossRef Venditto VJ, Simanek EE (2010) Cancer therapy utilizing the camptothecins: a review of the in vivo literature. Mole Pharmaceut 7:307–349CrossRef
2.
go back to reference Fassberg J, Stella VJ (1992) A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676–684PubMedCrossRef Fassberg J, Stella VJ (1992) A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81:676–684PubMedCrossRef
3.
go back to reference Mi Z, Burke TG (1994) Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325–10336PubMedCrossRef Mi Z, Burke TG (1994) Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33:10325–10336PubMedCrossRef
4.
go back to reference Ci T, Li T, Chang G et al (2013) Simply mixing with poly(ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family. J Control Release 169:252–258CrossRef Ci T, Li T, Chang G et al (2013) Simply mixing with poly(ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family. J Control Release 169:252–258CrossRef
5.
go back to reference Zhou JJ, Liu J, Xu B (2001) Relationship between lactone ring forms of HCPT and their antitumor activities. Acta Pharmacol Sin 22:827–830PubMed Zhou JJ, Liu J, Xu B (2001) Relationship between lactone ring forms of HCPT and their antitumor activities. Acta Pharmacol Sin 22:827–830PubMed
6.
go back to reference Zheng S, Chang S, Lu J et al (2011) Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. PLoS One 6:e21064PubMedCrossRef Zheng S, Chang S, Lu J et al (2011) Characterization of 9-nitrocamptothecin liposomes: anticancer properties and mechanisms on hepatocellular carcinoma in vitro and in vivo. PLoS One 6:e21064PubMedCrossRef
7.
go back to reference Scott DO, Bindra DS, Stella VJ (1993) Plasma pharmacokinetics of the lactone and carboxylate forms of 20(s)-camptothecin in anesthetized rats. Pharm Res 10:1451–1457PubMedCrossRef Scott DO, Bindra DS, Stella VJ (1993) Plasma pharmacokinetics of the lactone and carboxylate forms of 20(s)-camptothecin in anesthetized rats. Pharm Res 10:1451–1457PubMedCrossRef
8.
go back to reference Chen J, Hu RR, Yang XX et al (2012) Relationship between lactone ratios of 9-nitrocamptothecin and their lactone/carboxylate equilibria in vitro and in vivo. Lat Am J Pharm 31:990–998 Chen J, Hu RR, Yang XX et al (2012) Relationship between lactone ratios of 9-nitrocamptothecin and their lactone/carboxylate equilibria in vitro and in vivo. Lat Am J Pharm 31:990–998
9.
go back to reference Jiang Y, Jiang X, Law K et al (2011) Enhanced antitumor effect of 9-nitrocamptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation. Int J Pharm 415:252–258PubMedCrossRef Jiang Y, Jiang X, Law K et al (2011) Enhanced antitumor effect of 9-nitrocamptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation. Int J Pharm 415:252–258PubMedCrossRef
10.
go back to reference Chen J, Cai BC, Ping QN et al (2008) Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection. Drug Dev Ind Pharm 34:853–859PubMedCrossRef Chen J, Cai BC, Ping QN et al (2008) Lactone stability and tissue distribution of free and liposomal encapsulated 9-nitrocamptothecin in rats following intravenous injection. Drug Dev Ind Pharm 34:853–859PubMedCrossRef
11.
go back to reference Beretta GL, Zunino F (2007) Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochem Pharmacol 74:1437–1444PubMedCrossRef Beretta GL, Zunino F (2007) Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochem Pharmacol 74:1437–1444PubMedCrossRef
Metadata
Title
Antitumor efficacy, toxicity and pharmacokinetics of 9-nitrocamptothecin: role of lactone ratio
Authors
Jun Chen
Rong-Rong Hu
Xi-Xiong Yang
Wei Gu
Rong Tian
Fang Gong
Lei Luo
Fang Fang
Zhi-Peng Chen
Bao-Chang Cai
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-013-2259-x

Other articles of this Issue 4/2013

Cancer Chemotherapy and Pharmacology 4/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine